Sam Brusco, Associate Editor02.03.23
Varian (a Siemens Healthineers company) has earned U.S. Food and Drug Administration (FDA) 510(k) clearance and CE mark approval for its Halcyon and Ethos radiotherapy systems, which feature the company’s HyperSight imaging solution.
HyperSight helps capture high-quality patient images during daily radiation treatments. The images are used to localize tumors daily in order to replan and adapt to changes. Cone-beam computed tomography (CBCT), according to the company, produces larger images with better contrast and is 10x faster than typical linear accelerator-based imaging. (Traditional CBCT imaging can take up to a minute.)
The quantitative patient anatomy info (Hounsfield Units) allows radiation dose distributions to be calculated right on CBCT images—this previously required the patient to make another trip to a separate CT scanner. HyperSight performs this calculation directly on the linac-based CBCT imaging during treatment.
The tech might help adapt treatment to adjust for tumor anatomical changes as well as changes to surrounding organs.
"Varian has long been focused on pioneering innovations that can enhance the radiotherapy experience and outcomes for both patients and cancer care teams. Becoming a Siemens Healthineers company has given us an opportunity to sharpen and accelerate these efforts, with a focus on connecting the power of imaging inside and outside the treatment room," Kevin O'Reilly, president of Radiation Oncology Solutions at Varian, told the press. "HyperSight reflects the power of our expanded view of the patient journey and robust imaging technology. We look forward to working with our clinical partners and the broader radiotherapy community to drive adoption and further advancement of this technology, as we continue our work to transform the patient pathway and deliver on our mission to create a world without fear of cancer."
HyperSight helps capture high-quality patient images during daily radiation treatments. The images are used to localize tumors daily in order to replan and adapt to changes. Cone-beam computed tomography (CBCT), according to the company, produces larger images with better contrast and is 10x faster than typical linear accelerator-based imaging. (Traditional CBCT imaging can take up to a minute.)
The quantitative patient anatomy info (Hounsfield Units) allows radiation dose distributions to be calculated right on CBCT images—this previously required the patient to make another trip to a separate CT scanner. HyperSight performs this calculation directly on the linac-based CBCT imaging during treatment.
The tech might help adapt treatment to adjust for tumor anatomical changes as well as changes to surrounding organs.
"Varian has long been focused on pioneering innovations that can enhance the radiotherapy experience and outcomes for both patients and cancer care teams. Becoming a Siemens Healthineers company has given us an opportunity to sharpen and accelerate these efforts, with a focus on connecting the power of imaging inside and outside the treatment room," Kevin O'Reilly, president of Radiation Oncology Solutions at Varian, told the press. "HyperSight reflects the power of our expanded view of the patient journey and robust imaging technology. We look forward to working with our clinical partners and the broader radiotherapy community to drive adoption and further advancement of this technology, as we continue our work to transform the patient pathway and deliver on our mission to create a world without fear of cancer."